Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 10 Jun 2024 11:06:42 +0200Thu, 06 Jun 2024 13:26:00 +0200Human medicines European public assessment report (EPAR): Byfavo, remimazolam, Date of authorisation: 26/03/2021, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/byfavoHuman medicines European public assessment report (EPAR): Byfavo, remimazolam, Date of authorisation: 26/03/2021, Revision: 7, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/byfavoThu, 06 Jun 2024 13:26:00 +0200Human medicineByfavo : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5246_en_2.pdfByfavo : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5246_en_2.pdfThu, 06 Jun 2024 12:00:00 +0200Human medicine